Impaired function and delayed regeneration of dendritic cells in COVID-19

PLoS Pathog. 2021 Oct 6;17(10):e1009742. doi: 10.1371/journal.ppat.1009742. eCollection 2021 Oct.

Abstract

Disease manifestations in COVID-19 range from mild to severe illness associated with a dysregulated innate immune response. Alterations in function and regeneration of dendritic cells (DCs) and monocytes may contribute to immunopathology and influence adaptive immune responses in COVID-19 patients. We analyzed circulating DC and monocyte subsets in 65 hospitalized COVID-19 patients with mild/moderate or severe disease from acute illness to recovery and in healthy controls. Persisting reduction of all DC subpopulations was accompanied by an expansion of proliferating Lineage-HLADR+ cells lacking DC markers. Increased frequency of CD163+ CD14+ cells within the recently discovered DC3 subpopulation in patients with more severe disease was associated with systemic inflammation, activated T follicular helper cells, and antibody-secreting cells. Persistent downregulation of CD86 and upregulation of programmed death-ligand 1 (PD-L1) in conventional DCs (cDC2 and DC3) and classical monocytes associated with a reduced capacity to stimulate naïve CD4+ T cells correlated with disease severity. Long-lasting depletion and functional impairment of DCs and monocytes may have consequences for susceptibility to secondary infections and therapy of COVID-19 patients.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • Antigens, CD / immunology
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / pathology
  • COVID-19 / immunology*
  • COVID-19 / pathology
  • Dendritic Cells / immunology*
  • Dendritic Cells / pathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Monocytes / immunology
  • Monocytes / pathology
  • Programmed Cell Death 1 Receptor / immunology
  • Regeneration / immunology*
  • SARS-CoV-2 / immunology*

Substances

  • Antigens, CD
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor

Grants and funding

A.K. is supported by the Deutsche Forschungsgemeinschaft under SFB1054-TPA06 (210592381), SFB/TR237-B14 (369799452) and KR2199/10-1 (391217598), and received funding from the Bavarian State Ministry of Science and the Arts. E.W. received a scholarship from the Villigst Foundation. T.B. is supported by the Deutsche Forschungsgemeinschaft under SFB1054/TPB03 (210592381). M.S. was supported by the Deutsche Forschungsgemeinschaft under SFB 1243-A10 (278529602) and SU197/3-1 (451580403), the Bavarian Elite Graduate Training Network and the Wilhelm Sander Stiftung (project no. 2018.087.1). A.R. was supported by the Else-Kröner-Fresenius-Stiftung. D.B. was supported by Deutsche Forschungsgemeinschaft under Emmy Noether Programme BA 5132/1-2 (252623821), SFB1054/TPB12 (210592381), and Germany’s Excellence Strategy EXC2151 (390873048). S.R. was supported by the Deutsche Forschungsgemeinschaft under Ro 25257/-1 (391217598) and SFB/TR-237-B14 (369799452). K.S. is supported by the Deutsche Forschungsgemeinschaft under SFB914-TPB02 (165054336). A.H. and B.S. received funding from the Federal Ministry of Education and Research (BMBF) initiative “COMBAT C19IR” (01KI20249) with which proteome analysis was performed as presented in the manuscript. The CORKUM biobank is funded, in part, by the Federal Ministry of Education and Research (BMBF) initiative “NaFoUniMedCovid19” (01KX2021), LMUexcellent, the Free State of Bavaria under the Excellence Strategy of the Federal Government and the States, and the Faculty of Medicine of the LMU München. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.